Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Evotec SE, a drug discovery and development solutions company, today announced a partnership agreement with the University of Oxford regarding access to biospecimens from the biobank Quality in Organ Donation (QUOD), an initiative of the Nuffield Department of Surgical Sciences (NDS) at the University of Oxford in close collaboration with the National Health Service Blood and Transplant (NHSBT) organisation in the UK.

Quality in Organ Donation (QUOD) logo

The QUOD biobank is a joint programme by a consortium of UK academic transplant centres and NHSBT. The biobank is funded by NHSBT and the Medical Research Council and provides blood, urine and tissue samples from heart, lung, liver and kidney from consented organ donors for researchers with anonymised integrated medical records. The samples have been collected over several years with QUOD’s primary goal to identify biomarkers, explain mechanisms of injury and repair, and improve organ utilisation and transplantation. 

Under the terms of the partnership, Evotec will investigate at first samples from 1,000 donors of the QUOD biobank using a comprehensive multi-omics analysis (genomics, transcriptomics, proteomics, metabolomics). This data will complement Evotec’s existing patient database, generating a greater understanding of disease mechanisms across indications, i.e. cardio-vascular, kidney, and liver diseases. Investigation of diseased versus healthy human biomaterial using a multi-omics approach combined with clinical data will provide extensive knowledge, indispensable for advancement of organ transplantation, drug discovery as well as clinical and biomarker research.

The full story is available on the Nuffield Department of Surgical Sciences website

Similar stories

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.